probiome Sign in
← Conditions Mental health

Schizophrenia

Compared within 1 study that had both: 48 people with schizophrenia and 47 healthy people. 1 microbe is less common in people with schizophrenia, and none more common.

A difference is an association: it doesn’t mean these microbes cause, prevent or treat schizophrenia.

Searching opens both lists and shows only matching rows.

Less common in schizophrenia · 1

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people
  1. Collinsella tanakaei in 1 study Healthy 28% schizophrenia 4.2%

More common in schizophrenia · 0

Strongest first, then the biggest gap · Each figure is 10 people Strongest first · Each figure is 10 people

None compared.

Where these numbers come from

Studies
Only GMrepo projects that had people with the condition and healthy people, 10 or more of each. Numbers come from those studies, never from pooling.Sampled in China.
How common
The share of people whose sample has any of it, in the people with the condition and in the healthy people of those same studies. Tested within studies (Cochran–Mantel–Haenszel, corrected for testing many microbes); a difference counts when it is clear and meaningful (Cohen’s h of 0.2 or more).
Strength word
Counted by code from how many studies point the same way: Seen again and again (3 or more, none clearly the other way), Seen more than once (2, the majority), Seen once (1, listed last). Where studies disagree, a row isn’t listed.
Each study
Tap a row for every study’s own numbers, and for how much carriers have.
Analysis
Our analysis of GMrepo data. GMrepo on Data sources · Read the rules

Also compared · 244 microbes

Compared within studies that had both, but not listed above.

No meaningful difference · 244
PubMed · human studies and reviews first

Recent research

All research on it
  1. Schizophrenia research · 2026
    Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.
    PubMed ↗
  2. Review Progress in neuro-psychopharmacology & biological psychiatry · 2025
    Oropharyngeal microbiota in patients with psychotic disorders: A scoping review on compositional and functional alterations.
    PubMed ↗
  3. Observational Psychoneuroendocrinology · 2024
    Comparative analysis of gut microbiota in major depressive disorder and schizophrenia during hospitalisation - the case-control, post hoc study.
    PubMed ↗
  4. Brain, behavior, and immunity · 2024
    Reproducible gut microbial signatures in bipolar and schizophrenia spectrum disorders: A metagenome-wide study.
    PubMed ↗
  5. Observational Molecular neurobiology · 2021
    Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.
    PubMed ↗

Source: PubMed, U.S. National Library of Medicine · 11 linked papers, last 10 years